Dr. Nunzio Bottini

Nunzio Bottini, M.D., Ph.D, is a Professor of Medicine and currently serves as the Rheumatology Section Head in the Division of Rheumatology, Allergy and Immunology at UC San Diego. He received his M.D. in 1996 from the University of Rome, where he also obtained his Ph.D. and completed his internship and residency. He received postdoctoral research training in signal transduction at the Sanford Burnham Medical Prebys Medical Discovery Institute in La Jolla, and completed a clinical fellowship in Rheumatology at the University of California, San Diego. Dr. Bottini held appointments as an Assistant Professor at the University of Rome and the University of Southern California, and an Associate Professor at the La Jolla Institute for Allergy and Immunology.
Dr. Bottini serves on grant review panels for the NIH, the Rheumatology Research Foundation, and the Arthritis Foundation, and also serves as a reviewer for various scientific journals. He serves as the Director of the NIAMS-supported Microenvironment in Arthritis Research Center at UC San Diego. The ACTRI flow cytometry core is managed by Dr. Bottini and his laboratory personnel.

Personal motto: Nulla nos via tardat euntes.


About the Lab

The Bottini laboratory studies the mechanisms of action of signaling molecules encoded by human autoimmune disease-predisposing genes and analyses signal transduction pathways in pathological specimens from patients. The laboratory specializes in the study of a family of signaling enzymes called protein tyrosine phosphatases.

The first focus of the laboratory is on the mechanism of action of two phosphatase genes (PTPN22 and PTPN2) that strongly predispose to rheumatoid arthritis, type 1 diabetes, inflammatory bowel disease, and lupus. Our ultimate goal is to enable personalized therapies for autoimmune disease patients carrying specific genetic factors.

The second focus of the laboratory is on biochemical signaling in local joint-resident cells in rheumatoid arthritis with the goal of identifying targets for novel non-immunosuppressive therapies that would not increase the risk of infections.

The third focus is on biochemical signaling in cells that promote tissue scarring in systemic sclerosis and other fibrotic diseases with the goal of identifying targets for novel anti-fibrotic therapies.

      Lab News

  • Congrats to Sophie Hao who will begin a PhD program at Sanford-Burnham-Prebys in the fall!

  • Congrats to Anna Belongia who has been accepted to a PhD program at the University of Vermont!

  • Congrats to Colton Sanders who has been accepted to a PhD program at UCSF!

  • Congrats to Zachary Holmes who has been accepted to PhD programs at UCSD and UCSF!

  • Congrats to Tiffany Nguyen who who has been accepted to MD-PhD programs at UCLA, UCI, UNC, and UTSW.

  • Welcome to Akata Saha, a new post doc in the lab!

  • Congrats to Ruiyan Zhang, whose research article titled 'Oxidative stress promotes fibrosis in systemic sclerosis through stabilization of a kinase-phosphatase complex' has been provisionally accepted by JCI Insight!